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Abstract: Chronic obstructive pulmonary disease (COPD) is a
possible risk factor for cardiovascular disease. The association of COPD
with the pathogenicity of infection with Chlamydia pneumoniae and
Mycoplasma pneumoniae is controversial. We conducted a cross-sec-
tional study to clarify the association between atypical pneumoniae
seropositivity and COPD in a general population. We also investigated
genetic polymorphisms conferring susceptibility to a pneumonia titer.
The study included 9040 Japanese subjects (54 13 years). COPD
was defined as a ratio of forced expiratory volume in 1 second to forced
vital capacity of less than 70%. Serum levels of IgA and IgG antibodies
to C pneumoniae were determined using an enzyme-linked immunoas-
say, and M pneumoniae seropositivity was assessed by a particle
agglutination test.
Subjects seropositive for C pneumoniae (26.1%) had a higher
prevalence of COPD (seropositive, 5.8%; seronegative, 3.1%;
P< 0.001) after adjustment for age, sex, height, weight, and smoking
status. The association between M pneumoniae seropositivity (20.4%)
and COPD was also significant in covariate-adjusted analysis
(P< 0.001). A genome-wide association analysis of the C pneumoniae
IgA index identified a susceptible genotype (rs17634369) near the
IKZF1 gene, and the seropositive rate of C pneumoniae significantly
differed among genotypes (AA, 22.5; AG, 25.3; GG, 29.7%, P< 0.001).
On multiple regression analysis, seropositivity for both C pneumoniae
(odds ratio¼ 1.41, P¼ 0.004) and M pneumoniae (odds ratio¼ 1.60,
P¼ 0.002) was an independent determinant for COPD, while no direct
association was found with the rs17634369 genotype.
Seropositivity for both C pneumoniae and M pneumoniae is an
independent risk factor for COPD in the general population.
(Medicine 95(15):e3371)
Abbreviations: COPD = chronic obstructive pulmonary disease,
FEV1 = forced expiratory volume in 1 second, FVC = forced
vital capacity, GWAS = genome-wide association study, SLE =
systemic lupus erythematosus, SNP = single nucleotide
polymorphism.
INTRODUCTION
C hronic obstructive pulmonary disease (COPD), as assessedby forced expiratory volume in 1 second (FEV1) and forced
vital capacity (FVC), is an independent risk factor for the
incidence of cardiovascular diseases, including stroke,1 myo-
cardial infarction,2 and heart failure,3,4 as well as for dementia5
in the general population. COPD has also been associated with
increased mortality.6 Although the most important risk factor
for COPD is long-term smoking,7 only a small proportion of
smokers develop airflow obstruction,8 and some lifelong non-
smokers develop COPD.9 These inconsistent results suggest
that other risk factors are also causative in the pathogenesis
of COPD.
Factors postulated to play a role in the pathogenesis of
COPD to date include air pollution, respiratory infection in
childhood, bronchial hyperresponsiveness, systemic inflam-
mation, and genetic background.7,10,11 Infection with Chlamy-
dia pneumoniae (C pneumoniae), the most common nonviral
human respiratory pathogen, has also been proposed as a risk
factor for COPD.12 Although the mechanism by which chronic
infection with C pneumoniae might trigger the development of
COPD is not precisely understood, 1 plausible mechanism may
be the release of inflammatory cytokines and subsequent airway
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inflammation and tissue damage.12 Higher titers of C pneumo-
niae in blood specimens are commonly observed in patients
with respiratory diseases, namely COPD,13 chronic bronchi-
tis,14 and symptomatic respiratory disease,15 and in hospitalized
patients with acute exacerbation of COPD.16 Further, approxi-
mately 50% of cases of exacerbated COPD are caused by
bacterial infection, such as with C pneumoniae.17 Although
the prevalence and mortality of COPD are increasing world-
wide,18 the involvement ofC pneumoniae in the development of
COPD in the general population is largely unknown. Myco-
plasma pneumoniae (M pneumoniae) is another atypical
pathogen that causes community-acquired pneumonia. Infec-
tion or colonization of M pneumoniae in the lower airway is
associated with the pathogenesis of bronchial asthma,19
suggesting that chronic infection with M pneumoniae may also
be a risk factor for COPD.
Recent advances have enabled the analysis of millions of
single nucleotide polymorphisms (SNPs) dispersed throughout
the human genome. Genome-wide association studies (GWAS)
conducted without a prior hypothesis have successfully ident-
ified susceptibility loci for various common diseases and quan-
titative traits. GWAS of lung function have identified multiple
loci such as the hedgehog interacting protein (HHIP) and
glutathione S-transferase C-terminal domain containing
(GSTCD) gene region.20 Despite the possible existence of SNPs
which might influence susceptibility to seropositivity for pneu-
moniae, and the relationship between C pneumoniae and M
pneumoniae infection and pulmonary function, no study has yet
explored SNPs associated with seropositivity for both strains.
Here, we conducted a cross-sectional study to investigate
the association of C pneumoniae and M pneumoniae seroposi-
tivity with pulmonary function in a large general Japanese
population. We also conducted a GWAS to explore SNPs for
their association with seropositivity for both strains.
METHODS
Study Subjects
Study subjects were participants in the Nagahama Pro-
spective Genome Cohort for Comprehensive Human Bioscience
(the Nagahama Study). The Nagahama Study cohort was
recruited between 2008 and 2010 from the general population
(30–74 years old) living in Nagahama City, a largely suburban
city of 125,000 inhabitants in Shiga Prefecture. Nagahama City
residents aged 30 to 74 years at recruitment and without serious
health problems who agreed to participate in the cohort study of
their own accord were recruited via mass communications in the
local community, such as public relations magazines and
periodical newspapers.
Among a total of 9804 participants, we considered 9237
subjects as the total population in this study, consisting of 3246
subjects whose genome-wide SNP genotype data were available
and 5991 other subjects as a subset of the remaining samples
available for replication genotyping (Table S1, http://
links.lww.com/MD/A897). Among these, participants meeting
any of the following conditions were excluded from subsequent
association analysis for COPD: pregnancy (n¼ 40), history of
lung cancer (n¼ 19), unsuccessful assessment of the Brinkman
index (n¼ 23) or spirometric parameters (n¼ 24), and unavail-
ability of serum M pneumoniae titer (n¼ 1) or rs17634369
genotype (n¼ 90). Eventually, a total of 9040 people were
included as study subjects.
All study procedures were approved by the ethics com-
mittee of Kyoto University Graduate School of Medicine and
the Nagahama Municipal Review Board. Written informed
consent was obtained from all participants.
Basic Clinical Parameters
Clinical measurements and blood sampling were per-
formed at enrollment. Medical history and smoking status were
investigated using a structured questionnaire. The Brinkman
index was calculated as the daily number of cigarettes smoked
multiplied by the number of years spent smoking.
Evaluation of Pulmonary Function
Pulmonary function was measured by an FVCmaneuver on
a computed spirometer with automated quality checks (SP-350
COPD, Fukuda Denshi, Tokyo, Japan). Prebronchodilator spiro-
metrywasmeasured by certifiedmedical technologists in accord-
ance with a standardized protocol. COPD was defined by a ratio
of FEV1 to FVC of less than 70%. Predicted normal values for
FVC (FVC predicted) (L) and FEV1 (FEV1 predicted) (L) were
calculated using the following equations, in accordance with
guidelines developed by the Japanese Respiratory Society
for the diagnosis and treatment of COPD (3rd edition;
http://www.jrs.or.jp/uploads/uploads/files/photos/765.pdf): FVC
male¼ 0.042 height (cm) 0.024 age 1.785; FVC female
¼ 0.031 height 0.019 age 1.105; FEV1 male¼ 0.036
height 0.028 age 1.178; FEV1 female¼ 0.022 height
 0.022 age 0.005.
Measurement of C pneumoniae IgA and IgG
Indices
Levels of serum IgA and IgG antibodies to C pneumoniae
were determined using a specific enzyme-linked immunoassay
(ELISA) kit (HITAZYME C pneumoniae, Hitachi Chemical,
Tokyo, Japan) that detects antibodies to the chlamydial outer
membrane complex. IgA and IgG levels in each sample were
expressed as the IgA or IgG index, respectively. Seropositivity
to C pneumoniae was diagnosed as an IgA and IgG index value
of more than 1.1 for both. Details of the ELISA assay and
validity of the cut-off point have been described elsewhere.21
Mean intraassay coefficients of variation were 3.3% to 7.7% for
the IgA index and 6.3% to 9.0% for the IgG index. Respective
mean interassay coefficients of variation were 3.8% to 10.7%
and 4.0% to 10.7%.
Evaluation of M pneumoniae Seropositivity
M pneumoniae seropositivity was assessed using a semi-
quantitative particle agglutination test kit (Serodia-Myco II,
Fujirebio, Tokyo, Japan) consisting of gelatin particles coated
with cell membrane components of M pneumoniae (Mac
strain).22 Serum samples were serially diluted to give final
dilutions of 1:40 to 1:20, 480. According to the manufacturer’s
instructions, antibody titers of 1:40 and higher were considered
seropositive.23,24
Genome-Wide SNP Genotyping
DNAwas extracted from peripheral blood samples by the
phenol–chloroform method. Genome-wide SNP genotyping
was performed on 3710 samples of participants who joined
the Nagahama cohort from 2008 to 2009. A series of BeadChip
DNA arrays were used for analysis, namely HumanHap610
quad (1828 samples), HumanOmni2.5-4 (1616 samples),
HumanOmni2.5-8 (378 samples), HumanOmni2.5s (192
samples), and HumanExome (192 samples) (Illumina, San
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Diego, CA). Several samples were repeatedly genotyped using
different arrays. As a reference panel, 192 samples were geno-
typed using HumanOmni2.5-8, HumanOmni2.5s, and Huma-
nExome, and used in the following genotype imputation.
Genotyping quality was controlled by excluding SNPs with a
call rate below 99%, minor allele frequency below 0.01, or
extreme deviation from Hardy–Weinberg equilibrium
(P< 1.0 107). This threshold was defined to ensure a con-
cordance ratio of SNPs genotyped by different SNP arrays
greater than 99.99%.25 Genotype imputation was performed
by a standard 2-step procedure using MACH ver. 1.0.16 soft-
ware with 1792015 SNPs commonly genotyped in the 192
samples as a reference. Imputed SNPs with a minor allele
frequency of less than 0.01 or R2 less than 0.5 were excluded
from the following association analysis. Samples with a call rate
less than 95% (n¼ 162) were excluded from analysis. Of the
remaining 3548 subjects, 295 individuals were excluded as they
showed high degrees of kinship (Pi-hat greater than 0.35,
PLINK ver. 1.07), and 7 individuals were excluded as ancestry
outliers, as identified by principal component analysis using the
HapMap Phase 2 release 28 JPT dataset as reference (EIGEN-
STRAT ver. 2.0).
Replication Genotyping
Replication analysis was performed with a subset of the
remaining samples from the Nagahama cohort (n¼ 5991).
Genotypes were analyzed with a TaqMan probe assay using
commercially available primer and probe sets purchased from
Life Technologies Corporation (Carlsbad, CA). Fluorescence
level of PCR products was measured using the 7900HT Fast
Real-Time PCR System (Life Technologies).
Statistical Analysis
Genome-wide association analysis of the C pneumoniae
IgA and IgG index values was performed by linear regression
analysis under an additive genetic model adjusted for age, age-
squared, sex, and body mass index, while analysis of M pneu-
moniae seropositivity was performed by a Chi-square test
(PLINK). Rank-based inverse normal transformation was
applied to the C pneumoniae IgA and IgG index values.
Population stratification was adjusted using top principal com-
ponents as covariates. Given an estimation of the appropriate
testing burden in a GWAS in Europeans as a million, a P-value
less than 5.0 108 was considered to have genome-wide
significance.26 Based on findings that an additive model has
reasonable power in detecting both additive and dominant
effects,27 we applied only an additive model in the
current GWAS.
In other association analyses, differences in numeric vari-
ables among subgroups were assessed by analysis of variance,
while differences in frequency were assessed by a Chi-square
test. Factors independently associated with COPD were ident-
ified by multiple logistic regression analysis. All statistical
analyses were performed using JMP 9.0.2 software (SAS
Institute, Cary, NC), with a conventional P-value less than
0.05 considered to indicate statistical significance.
RESULTS
Table 1 shows the clinical characteristics of the study
subjects. A total of 341 (3.8%) subjects were diagnosed with
COPD. Subjects with COPD were significantly older (COPD
61 12 vs control 53 13 years, P< 0.001), and mostly male
(61.0% vs 31.6%, P< 0.001) and current or past smokers
(58.7% vs 33.8%, P< 0.001). Differences in major clinical
parameters by severity of pulmonary function are detailed in
Table S2, http://links.lww.com/MD/A897.
C pneumoniae and M pneumoniae Seropositivity
With Pulmonary Function
The frequency of C pneumoniae and M pneumoniae
seropositivity was 26.1% and 20.4%, respectively. The number
of subjects seropositive for C pneumoniae increased with age,
whereas that for M pneumoniae showed the opposite relation-
ship (Figure S1, http://links.lww.com/MD/A897). Associations
of seropositivity for both strains with pulmonary function are
summarized in Table 2 and Figure S2, http://links.lww.com/
MD/A897. Subjects seropositive for C pneumoniae exhibited
significantly lower pulmonary function and a higher frequency
of COPD. Although the values of the C pneumonia e IgA and
IgG indices were linearly associated with smoking intensity as
assessed by the Brinkman index (Figure 1), significantly lower
pulmonary function in seropositive subjects remained after
adjustment for the interrelationships (Table 2). Conversely,
the pulmonary function of subjects seropositive for M pneu-
moniae was slightly better than that of seronegative subjects
(Table 2), but these associations were lost after adjustment for
covariates, including age, presumably due to the markedly
younger age of seropositive subjects. In contrast, the association
between M pneumoniae seropositivity and COPD became
significant in the covariate-adjusted analysis (odds
ratio¼ 1.63). Similar results were observed in an analysis which
excluded subjects receiving treatment for asthma or COPD
(n¼ 90) (Table S3, http://links.lww.com/MD/A897).
GWAS of C pneumoniae IgA and IgG Indices
GWAS of the C pneumoniae IgA index values identified
strong association signals at 6p22.3 (rs9460391, b¼ 0.163,
P¼ 6.9 108), 7p12 (rs17634369, b¼ 0.134, P¼ 3.0 108),
8), and 13q33 (rs942102, b¼0.134, P¼ 7.7 108) (Figure
S3, Table S4, http://links.lww.com/MD/A897). Additional gen-
ome-wide significant signals were found in the human leukocyte
antigen gene region, but these were lost after adjustment for
population stratification (Figures S4 and S5, http://links.lww.-
com/MD/A897). No significant signals were found in GWAS of
the C pneumoniae IgG index value (Figures S3 and S4, http://
links.lww.com/MD/A897), or in analysis of M pneumoniae
seropositivity (Figure S6, http://links.lww.com/MD/A897). Stat-
istical power of the GWAS is shown in Figure S8, http://
links.lww.com/MD/A897. Additional susceptible SNPs with a
lower frequency or smaller effect size might be detectable with a
greater number of subjects.
Replication Analysis for the Candidate SNPs
Replication analysis of the remaining Nagahama samples
confirmed the positive association of rs17634369 (b¼ 0.080,
P¼ 1.4 105), but not rs9460391 (P¼ 0.414) or rs942102
(P¼ 0.621) (Table S4, http://links.lww.com/MD/A897). Per-
allele effect size of rs17634369 on the C pneumoniae IgA
index value calculated from the combined datasets used in
the GWAS, and replication analysis was approximately 0.1
(P¼ 1.3 1011). SNP rs17634369 was located approximately
22 kb upstream of the IKZF1 gene, where no other genes were
mapped (Figure S7, http://links.lww.com/MD/A897), and was
in strong linkage disequilibrium with the SNP rs4917014
(D0 ¼ 0.921, r2¼ 0.773), which was previously identified as
conferring susceptibility to systemic lupus erythematosus
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(SLE).28 There were no significant associations between pre-
viously validated SNPs for SLE and C pneumoniae IgA index
value (Table S5, http://links.lww.com/MD/A897).
SNP rs17634369 and C pneumoniae IgA Index
Figure 2A shows the differences in the C pneumoniae IgA
index values for the rs17634369 genotype. Subjects with the G
allele showed a significantly higher IgA index value. The
seropositive rate of C pneumoniae defined by the IgA index
(Figure 2B) and the IgA and IgG indices (Figure 2C) linearly
increased with the number of G alleles. Associations between
the rs17634369 genotype and C pneumoniae IgA index value
(P< 0.001), as well as the seropositive rate defined by IgA and
IgG indices (P< 0.001), remained significant after adjustment
for age, sex, and smoking status.
Multivariate Analysis for COPD
A multiple logistic regression analysis was used to further
identify factors independently associated with COPD (Table 3).
Results showed that both C pneumoniae and M pneumoniae
seropositivity were independently associated with COPD
(Model 1), even when individuals taking medication for asthma
and COPD were excluded (Table S6, http://links.lww.com/MD/
A897), while the rs17634369 genotype was not directly associ-
ated with COPD (Model 1), even following adjustment for C
pneumoniae and M pneumoniae seropositivity (Model 2). In a
separate analysis by smoking status, positive associations
between pneumoniae seropositivity and COPD were observed
only in current or past smokers (Model 3), and not in never-
smokers (Model 4). No interaction was observed between the
rs17634369 genotype and C pneumoniae seropositivity
(P¼ 0.846).
TABLE 1. Clinical Characteristics of Study Subjects (n¼9040)
Age, years 54 13
Sex (male/female) 2953/6087
Body height, cm 160.0 8.4
Body weight, kg 57.3 10.9
Body mass index, kg/m2 22.3 3.3
Smoking (current/past/never) 1309/1832/5899
Brinkman index in current or past
smokers
466 389
FVC, L 3.25 0.83
FVC % predicted, % 105 15
FEV1, L 2.67 0.67
FEV1/FVC 82.3 6.6
FEV1 % predicted, % 103 16
Medication for COPD (n) 21
Medication for asthma (n) 75
COPD (n) 341
C pneumoniae IgG index 1.19 0.74
C pneumoniae IgA index 0.99 0.64




Values are mean standard deviation. Predicted normal values for
FVC (FVC predicted) and FEV1 (FEV1 predicted) were calculated using
the following prediction equations developed by the Japanese Respir-
atory Society: FVC male (L)¼ 0.042 height (cm) 0.024 age
(years) 1.785; FVC female¼ 0.031 height 0.019 age 1.105;
FEV1 male¼ 0.036 height 0.028 age 1.178; and FEV1 fema-
le¼ 0.022 height 0.022 age 0.005.COPD was defined as a ratio
of FEV1 to FVC of less than 70%. COPD¼ chronic obstructive pul-
monary disease, FEV1¼ forced expiratory volume in 1 second,
FVC¼ forced vital capacity.
TABLE 2. Differences in Clinical Parameters of C pneumoniae and M pneumoniae Seropositive Patients











Crude Adjusted Crude Adjusted
Age, years 53 13 56 13 <0.001 56 13 47 13 <0.001
Sex (male %) 30.5 38.9 <0.001 35.0 23.4 <0.001
Body height, cm 159.8 8.4 160.3 8.4 0.021 159.9 8.6 160.1 7.8 0.289
Body weight, kg 57.0 10.8 58.1 11.0 <0.001 57.7 10.9 55.6 10.7 <0.001
Body mass index,
kg/m2
22.2 3.3 22.5 3.3 <0.001 22.5 3.3 21.6 3.3 <0.001
Smoking (current or
past %)
32.2 41.9 <0.001 34.5 35.6 0.391
FVC, L 3.26 0.84 3.22 0.80 0.038 <0.001 3.24 0.84 3.32 0.80 <0.001 0.154
FVC % predicted, % 105 15 103 16 <0.001 <0.001 105 15 104 15 0.366 0.338
FEV1, L 2.69 0.68 2.61 0.65 <0.001 <0.001 2.64 0.68 2.75 0.66 <0.001 0.017
FEV1% predicted, % 104 16 101 17 <0.001 <0.001 104 16 103 16 0.060 0.092
FEV1/FVC, % 82.6 6.4 81.3 7.3 <0.001 0.001 82.0 6.5 83.3 7.1 <0.001 0.105
COPD, % 3.1 5.8 <0.001 0.002 3.7 3.9 0.734 0.001
Values are mean standard deviation. Chronic obstructive pulmonary disease (COPD) indicates chronic obstructive pulmonary disease.
Seropositivity of C pneumoniae was defined as IgA and IgG index values of both more than 1.1. Titers of antibody to M pneumoniae greater
than 1:40 were considered as seropositive. Differences in clinical parameters were assessed by analysis of variance, while differences in frequency
were evaluated by the chi-square test. P-values adjusted for age, sex, body height, body weight, and Brinkman index were calculated by multiple
regression analyses.
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DISCUSSION
In this study, we demonstrated that seropositivity for C
pneumoniae and M pneumoniae was positively associated with
COPD. To our knowledge, this is the 1st study to clearly show
the risk of C pneumoniae and M pneumoniae seropositivity for
COPD in a general population, particularly in smokers. Further,
we identified SNPs conferring susceptibility for C pneumoniae
seropositivity, although no direct association with COPD
was observed.
Although several studies reported that patients with COPD
had a significantly higher titer of serum C pneumoniae IgA or
IgG,13–15 the East London COPD study in 110 patients with
stable COPD reported an inconsistent result.29 A plausible
reason for this discrepancy is insufficient statistical power
due to the relatively small sample size. For example, von
Hertzen et al13 compared IgA and IgG titers in 54 COPD
patients and 321 healthy controls, and Brande´n et al15 inves-
tigated the association of chronic C pneumoniae infection with
longstanding airway symptoms in 199 patients, of whom 30
were diagnosed with COPD. In a general population, 1 study
investigated the association of C pneumoniae infection with
pulmonary function in 1773 men30 and failed to find any
association with outcome measures, including baseline spiro-
metric parameters and FEV1 decline during the 5-year follow-
up period. However, the frequency of current or past smokers in
the previous study (>80%) was more than double that in our
present study, and more than double that in the National Survey
on Circulatory Disorders of Japan,31 which reported that the
frequency of current or past smokers in Japan is approximately
40%. The harmful effects of smoking might therefore render the
potential pathogenicity of C pneumoniae infection undetect-
able. Given that our present study was based on a large
population with a ratio of smokers to nonsmokers equivalent
to that of the national survey, our observations may provide
strong evidence thatC pneumoniae seropositivity is a risk factor
for reduced pulmonary function in general populations.
Mpneumoniae is another atypical pathogen of community-
acquired pneumonia. Although several small studies reported a
possible risk of serologically identifiedM pneumoniae for acute
exacerbation of COPD,32,33 other studies denied this etiological
FIGURE 2. Association of rs17634369 genotype withC pneumoniae IgA index value and seropositivity. (A) Box plot ofC pneumonia e IgA
index by rs17634369 genotype. Number of subjects for each genotype is shown in parentheses. Statistical significance was assessed by
analysis of variance. (B) Seropositivity of C pneumoniae defined by the IgA index. An IgA index value of more than 1.1 was considered as
seropositive. Statistical significance was assessed by the Chi-square test. (C) Seropositivity of C pneumonia e defined by the IgA or IgG
index. Seropositivity was defined as IgA and IgG index values of more than 1.1 for both.
FIGURE 1. Mean IgA and IgG indices by smoking status and
quartile of Brinkman index. Values are mean standard deviation
of IgG (A) and IgA (B) indices. Smokers were divided into quartiles
according to Brinkman index (Q1:<159.7, Q2: 160.0–374.0, Q3:
375.0–684.8, Q4: 685.0–2784). Numbers of subjects in each
subgroup are shown in the column. Statistical significance was
assessed by analysis of covariance and post-hoc analysis was
performed by Dunnett test.
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relationship.34,35 Clinical and epidemiological data on the
pulmonary risk of M pneumoniae infection is thus limited
and conflicting even in COPD patients. In addition, no data
are available on the association between M pneumoniae infec-
tion and spirometric parameters. Our present findings are there-
fore important in helping to elucidate the pulmonary risk of M
pneumoniae infection in a general population. Further, the risk
of M pneumoniae infection was equal to or somewhat greater
than that of C pneumoniae. Of note, however, subjects infected
with M pneumoniae first appeared to have better pulmonary
function, presumably due to their younger age.
In general populations, even mild to moderate airflow
limitation and COPD have been suggested to confer a risk
for the incidence of cardiovascular diseases.2–5 One potential
factor in explaining the possible relationship between COPD
and cardiovascular outcomes is atherosclerosis.36 Given that the
present and previous reports showed a positive association
between C pneumoniae seropositivity and atherosclerotic vas-
cular change,37,38 as well as cardiovascular and all-cause
mortality,39 C pneumoniae infection might be a factor under-
lying the relationship between COPD and cardiovascular out-
comes.
The rs17634369 genotype was significantly associated
with the seropositive prevalence of C pneumoniae. According
to the Encyclopedia of DNA Elements (ENCODE) project
datasets (UCSC genome browser: http://genome.ucsc.edu/), this
polymorphism lies approximately 22 kb upstream of the IKZF1
gene. A recent systemic expression quantitative trait locus
(eQTL) analysis40 found that the T allele of the rs4917014
genotype, a proxy of the G allele of the rs17634369 genotype,
was associated with increased expression of the IKZF1 gene
(cis-effect). Further, very recently, the rs4917014 genotype was
identified as susceptible for cold medicine-related Stevens–
Johnson syndrome via a mechanism involving a change in the
quantitative ratio of the IKZF1 alternative splicing isoforms Ik1
and Ik2.41 Although we did not perform functional analysis for
the relationship between rs17634369 or rs4917014 genotype
and C pneumoniae Ig A index, these previous results are
sufficient to consider IKZF1 as a factor in C
pneumoniae seropositivity.
IKZF1 encodes the transcription factor ‘‘Ikaros.’’ Ikaros
was reported to be associated with transcriptional regulation of
human STAT4,42 which is involved in cell-mediated immune
responses via Th1 cell development.43 The STAT4 pathway
may therefore help explain the association between IKZF1
genotype and C pneumoniae seropositivity. The eQTL analysis
also reported a significant association between the rs4917014
genotype and increased expression of genes involved in the type
1 interferon response (trans-effect).40 Given that increased
expression of interferon-a response genes is a distinct expres-
sion pattern in SLE patients,44 and that the rs4917014 genotype
confers susceptibility to SLE,28 the increased C pneumoniae
IgA levels and higher risk of SLE in individuals with the risk
allele might partially share a common pathophysiological path-
way.
The microimmunofluorescence (MIF) test is currently the
objective standard for the serodiagnosis of C pneumoniae, but
interlaboratory variability is an unanswered issue. An ELISA is
another convenient method of serodiagnosis. However, discre-
pancies in the detection ratio between indirect (MIF, ELISA)
and direct (PCR) methods remain to be resolved. Our present
findings may suggest that the discrepancy in detection ratio
among populations, which plays at least some role in the
controversy over C pneumoniae infection in chronic inflam-
matory diseases, may in part be due to genetic heritability.45
Several limitations of our study warrant mention. First, we
could not distinguish between persistent and past infection of
pneumoniae by measuring seropositivity. Although the pre-
sence of pneumoniae antibodies may reflect the presence of
prior infection, this may not be a valid measure of persistent and
chronic active reinfection. A guideline from a workshop on the
standardization of C pneumoniae diagnostic methods46
suggested that no valid serological marker specific for chronic
C pneumoniae infection is available and that any interpretation
of infection status on the basis of single titer readings should be
done with care. Second, we might not have entirely excluded
subjects with bronchial asthma due to a lack of postbroncho-
dilator spirometry values, or subjects with other pulmonary
diseases such as diffuse bronchiectasis and bronchiolitis oblit-
erans. Given the positive association between atypical bacterial
infection and asthma,47 our findings might have been con-
founded by interaction with the reversible airflow obstruction.
However, our observed positive association between C pneu-
moniae and M pneumoniae seropositivity and COPD remained
TABLE 3. Multiple Logistic Regression Analysis for Chronic Obstructive Pulmonary Disease (COPD)




Model 1 Model 2 Model 3 Model 4
Age (10 years) 1.65 (1.47–1.86) <0.001 1.69 (1.51–1.91) <0.001 1.87 (1.57–2.25) <0.001 1.59 (1.34–1.88) <0.001
Sex (male) 1.16 (0.78–1.72) 0.448 1.16 (0.78–1.72) 0.453 0.75 (0.41–1.38) 0.348 1.47 (0.81–2.62) 0.201
Body height, cm 1.08 (1.06–1.11) <0.001 1.08 (1.06–1.11) <0.001 1.08 (1.05–1.12) <0.001 1.08 (1.05–1.12) <0.001
Body weight, kg 0.95 (0.94–0.96) <0.001 0.95 (0.94–0.97) <0.001 0.95 (0.93–0.97) <0.001 0.95 (0.93–0.98) <0.001
Brinkman index (100
index)
1.11 (1.08–1.14) <0.001 1.10 (1.07–1.14) <0.001 1.11 (1.07–1.15) <0.001
C pneumoniae
seropositive
1.41 (1.11–1.78) 0.004 1.49 (1.10–2.03) 0.010 1.27 (0.87–1.84) 0.213
M pneumoniae
seropositive
1.60 (1.20–2.12) 0.002 1.85 (1.25–2.70) 0.002 1.33 (0.84–2.04) 0.212
rs17634369 genotype
(per allele)
1.10 (0.94–1.29) 0.229 1.09 (0.93–1.33) 0.309 1.11 (0.90–1.38) 0.316 1.11 (0.69–1.80) 0.671
Values are odds ratio (95% confidence interval) and P-value.
Muro et al Medicine  Volume 95, Number 15, April 2016
6 | www.md-journal.com Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
significant after the exclusion of subjects with self-reported
medication for bronchial asthma or COPD, or with pulmonary
disease. Third, as our study subjects were Japanese, the results
of this study might not be simply extrapolatable to other
populations with different environmental backgrounds. Further,
the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/
SNP/) shows ethnic differences in the rs17634369 genotype,
with the highest frequency of the G allele in Africans, followed
by Asians and Caucasians.
In summary, our study clarified that dual C pneumoniae
and M pneumoniae seropositivity is an independent risk factor
for pulmonary function. Further investigations are needed to
clarify mechanisms regarding the disease pathogenicity of
pneumoniae infection.
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